Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Edoxaban Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,911Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 1Edoxaban

    02 11Lixiana

    03 4Savaysa

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Lixiana

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 707

    2019 Revenue in Millions : 745

    Growth (%) : -5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Lixiana

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 676

    2019 Revenue in Millions : 516

    Growth (%) : 31

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Savaysa

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Savaysa

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 28

    2019 Revenue in Millions : 25

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Lixiana

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 743

    2020 Revenue in Millions : 703

    Growth (%) : 14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Lixiana

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 802

    2020 Revenue in Millions : 672

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Lixiana

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 781

    2021 Revenue in Millions : 743

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Lixiana

    Edoxaban

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 849

    2021 Revenue in Millions : 802

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Lixiana

    Edoxaban

    arrow
    PackExpo
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    PackExpo
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 780

    2022 Revenue in Millions : 781

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Lixiana

    Edoxaban Tosylate

    arrow
    2024 ACI Convention
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    2024 ACI Convention
    Not Confirmed

    Daiichi Sankyo

    Edoxaban Tosylate

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 926

    2022 Revenue in Millions : 849

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Lixiana

    Edoxaban

    arrow
    PackExpo
    Not Confirmed

    Brand Name : Lixiana

    Japan
    arrow
    PackExpo
    Not Confirmed

    Daiichi Sankyo

    Edoxaban

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2017 Revenue in Millions : 278

    2016 Revenue in Millions : 617

    Growth (%) : -55

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF